Skip to main content

Table 4 Changes in the concomitant immunosuppressants use before and after the introduction of MPZ

From: Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis

Case No. Pre-MPZ Post-MPZ
− 12 months − 11 months − 9 months − 6 months 0 months 1 months 3 months 6 months 12 months
1 MTX 8 mg MTX 8 mg None None None None None None None
2 MTX 8 mg+AZ 125 mg MTX 8 mg+AZ 125 mg MTX 8 mg+AZ 125 mg MTX 8 mg+AZ 125 mg MTX 8 mg+AZ 125 mg AZ125 mg AZ125 mg AZ125 mg AZ100 mg
3 AZ50 mg AZ50 mg AZ 50 mg AZ 50 mg AZ 50 mg AZ 50 mg AZ 50 mg AZ 50 mg AZ 50 mg
4 None None AZ 50 mg None None None None MTX 8 mg MTX 8 mg
5 MTX 6 mg+AZ 50 mg MTX 6 mg+AZ 50 mg MTX 6 mg+AZ 50 mg MTX 6 mg+AZ 50 mg MTX 6 mg+AZ 50 mg AZ 50 mg AZ 50 mg AZ 50 mg AZ 50 mg
6 MTX 16 mg MTX 16 mg MTX 16 mg MTX 16 mg MTX 16 mg MTX 16 mg MTX 10 mg MTX 4 mg None
7 None None None None None None None None None
8 MTX 12 mg MTX 12 mg MTX 12 mg MTX 12 mg MTX 12 mg None None None None
9 AZ 50 mg AZ 50 mg AZ 50 mg AZ 50 mg AZ 50 mg None None None None
10 None None IVCY None None None None None None
11 TAC 3 mg TAC 3 mg TAC 3 mg TAC 3 mg TAC 3 mg None None None None
12 None None None None None None None None None
13 AZ 50 mg AZ 50 mg AZ 50 mg AZ 50 mg AZ 50 mg AZ 50 mg AZ 50 mg AZ 50 mg AZ 50 mg
14 None None None None None None None None None
15 AZ 100 mg AZ 100 mg AZ 100 mg AZ 100 mg AZ 100 mg None None None None
16 None None None None None None None None None
  1. IVCY cyclophosphamide pulse therapy i.v., MTX methotrexate, AZ azathioprine, TAC tacrolimus